Pain in Neurodegenerative Disease: Current Knowledge and Future Perspectives

Marina De Tommaso, Lars Arendt-Nielsen, Ruth Defrin, Miriam Kunz, Gisele Pickering, Massimiliano Valeriani

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Neurodegenerative diseases are going to increase as the life expectancy is getting longer. The management of neurodegenerative diseases such as Alzheimer's disease (AD) and other dementias, Parkinson's disease (PD) and PD related disorders, motor neuron diseases (MND), Huntington's disease (HD), spinocerebellar ataxia (SCA), and spinal muscular atrophy (SMA), is mainly addressed to motor and cognitive impairment, with special care to vital functions as breathing and feeding. Many of these patients complain of painful symptoms though their origin is variable, and their presence is frequently not considered in the treatment guidelines, leaving their management to the decision of the clinicians alone. However, studies focusing on pain frequency in such disorders suggest a high prevalence of pain in selected populations from 38 to 75% in AD, 40% to 86% in PD, and 19 to 85% in MND. The methods of pain assessment vary between studies so the type of pain has been rarely reported. However, a prevalent nonneuropathic origin of pain emerged for MND and PD. In AD, no data on pain features are available. No controlled therapeutic trials and guidelines are currently available. Given the relevance of pain in neurodegenerative disorders, the comprehensive understanding of mechanisms and predisposing factors, the application and validation of specific scales, and new specific therapeutic trials are needed.

Original languageEnglish
Article number7576292
JournalBehavioural Neurology
Volume2016
DOIs
Publication statusPublished - 2016

Fingerprint

Neurodegenerative Diseases
Pain
Motor Neuron Disease
Parkinson Disease
Alzheimer Disease
Guidelines
Spinocerebellar Ataxias
Spinal Muscular Atrophy
Huntington Disease
Pain Measurement
Life Expectancy
Causality
Dementia
Respiration
Therapeutics
Population

ASJC Scopus subject areas

  • Neuropsychology and Physiological Psychology
  • Clinical Neurology
  • Neurology

Cite this

De Tommaso, M., Arendt-Nielsen, L., Defrin, R., Kunz, M., Pickering, G., & Valeriani, M. (2016). Pain in Neurodegenerative Disease: Current Knowledge and Future Perspectives. Behavioural Neurology, 2016, [7576292]. https://doi.org/10.1155/2016/7576292

Pain in Neurodegenerative Disease : Current Knowledge and Future Perspectives. / De Tommaso, Marina; Arendt-Nielsen, Lars; Defrin, Ruth; Kunz, Miriam; Pickering, Gisele; Valeriani, Massimiliano.

In: Behavioural Neurology, Vol. 2016, 7576292, 2016.

Research output: Contribution to journalReview article

De Tommaso, M, Arendt-Nielsen, L, Defrin, R, Kunz, M, Pickering, G & Valeriani, M 2016, 'Pain in Neurodegenerative Disease: Current Knowledge and Future Perspectives', Behavioural Neurology, vol. 2016, 7576292. https://doi.org/10.1155/2016/7576292
De Tommaso, Marina ; Arendt-Nielsen, Lars ; Defrin, Ruth ; Kunz, Miriam ; Pickering, Gisele ; Valeriani, Massimiliano. / Pain in Neurodegenerative Disease : Current Knowledge and Future Perspectives. In: Behavioural Neurology. 2016 ; Vol. 2016.
@article{1e7cf342301049759e3d6c9849d096ab,
title = "Pain in Neurodegenerative Disease: Current Knowledge and Future Perspectives",
abstract = "Neurodegenerative diseases are going to increase as the life expectancy is getting longer. The management of neurodegenerative diseases such as Alzheimer's disease (AD) and other dementias, Parkinson's disease (PD) and PD related disorders, motor neuron diseases (MND), Huntington's disease (HD), spinocerebellar ataxia (SCA), and spinal muscular atrophy (SMA), is mainly addressed to motor and cognitive impairment, with special care to vital functions as breathing and feeding. Many of these patients complain of painful symptoms though their origin is variable, and their presence is frequently not considered in the treatment guidelines, leaving their management to the decision of the clinicians alone. However, studies focusing on pain frequency in such disorders suggest a high prevalence of pain in selected populations from 38 to 75{\%} in AD, 40{\%} to 86{\%} in PD, and 19 to 85{\%} in MND. The methods of pain assessment vary between studies so the type of pain has been rarely reported. However, a prevalent nonneuropathic origin of pain emerged for MND and PD. In AD, no data on pain features are available. No controlled therapeutic trials and guidelines are currently available. Given the relevance of pain in neurodegenerative disorders, the comprehensive understanding of mechanisms and predisposing factors, the application and validation of specific scales, and new specific therapeutic trials are needed.",
author = "{De Tommaso}, Marina and Lars Arendt-Nielsen and Ruth Defrin and Miriam Kunz and Gisele Pickering and Massimiliano Valeriani",
year = "2016",
doi = "10.1155/2016/7576292",
language = "English",
volume = "2016",
journal = "Behavioural Neurology",
issn = "0953-4180",
publisher = "HINDAWI LTD",

}

TY - JOUR

T1 - Pain in Neurodegenerative Disease

T2 - Current Knowledge and Future Perspectives

AU - De Tommaso, Marina

AU - Arendt-Nielsen, Lars

AU - Defrin, Ruth

AU - Kunz, Miriam

AU - Pickering, Gisele

AU - Valeriani, Massimiliano

PY - 2016

Y1 - 2016

N2 - Neurodegenerative diseases are going to increase as the life expectancy is getting longer. The management of neurodegenerative diseases such as Alzheimer's disease (AD) and other dementias, Parkinson's disease (PD) and PD related disorders, motor neuron diseases (MND), Huntington's disease (HD), spinocerebellar ataxia (SCA), and spinal muscular atrophy (SMA), is mainly addressed to motor and cognitive impairment, with special care to vital functions as breathing and feeding. Many of these patients complain of painful symptoms though their origin is variable, and their presence is frequently not considered in the treatment guidelines, leaving their management to the decision of the clinicians alone. However, studies focusing on pain frequency in such disorders suggest a high prevalence of pain in selected populations from 38 to 75% in AD, 40% to 86% in PD, and 19 to 85% in MND. The methods of pain assessment vary between studies so the type of pain has been rarely reported. However, a prevalent nonneuropathic origin of pain emerged for MND and PD. In AD, no data on pain features are available. No controlled therapeutic trials and guidelines are currently available. Given the relevance of pain in neurodegenerative disorders, the comprehensive understanding of mechanisms and predisposing factors, the application and validation of specific scales, and new specific therapeutic trials are needed.

AB - Neurodegenerative diseases are going to increase as the life expectancy is getting longer. The management of neurodegenerative diseases such as Alzheimer's disease (AD) and other dementias, Parkinson's disease (PD) and PD related disorders, motor neuron diseases (MND), Huntington's disease (HD), spinocerebellar ataxia (SCA), and spinal muscular atrophy (SMA), is mainly addressed to motor and cognitive impairment, with special care to vital functions as breathing and feeding. Many of these patients complain of painful symptoms though their origin is variable, and their presence is frequently not considered in the treatment guidelines, leaving their management to the decision of the clinicians alone. However, studies focusing on pain frequency in such disorders suggest a high prevalence of pain in selected populations from 38 to 75% in AD, 40% to 86% in PD, and 19 to 85% in MND. The methods of pain assessment vary between studies so the type of pain has been rarely reported. However, a prevalent nonneuropathic origin of pain emerged for MND and PD. In AD, no data on pain features are available. No controlled therapeutic trials and guidelines are currently available. Given the relevance of pain in neurodegenerative disorders, the comprehensive understanding of mechanisms and predisposing factors, the application and validation of specific scales, and new specific therapeutic trials are needed.

UR - http://www.scopus.com/inward/record.url?scp=84975284912&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84975284912&partnerID=8YFLogxK

U2 - 10.1155/2016/7576292

DO - 10.1155/2016/7576292

M3 - Review article

AN - SCOPUS:84975284912

VL - 2016

JO - Behavioural Neurology

JF - Behavioural Neurology

SN - 0953-4180

M1 - 7576292

ER -